4-碘-DL-苯甘氨酸 | 299167-68-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-碘-DL-苯甘氨酸
• 中文别名: RS-4-碘苯甘氨酸；2-氨基-2-(4-碘苯基)乙酸
• 英文名称: Amino-(4-iodo-phenyl)-acetic acid
• 英文别名: 2-azaniumyl-2-(4-iodophenyl)acetate
• CAS: 299167-68-3
• 化学式: C₈H₈INO₂
• mdl: MFCD02662474
• 分子量: 277.062
• InChiKey: SHUIEJDVWZHDTI-UHFFFAOYSA-N

物化性质

• 沸点：
  363.8±37.0 °C(Predicted)
• 密度：
  1.932±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：US20150175541A1

  公开（公告）日：2015-06-25

  There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I′): (in the above-mentioned general formula (I′), W, Y, R 2 , R 3 , R 4 , and Y 4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

  提供了一些化合物，具有优越的PHD2抑制作用，其通式表示为(I'):(在上述通式(I')中，W、Y、R2、R3、R4和Y4如上所述)，或其药学上可接受的盐。
• OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS.
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2499121A1

  公开（公告）日：2012-09-19
• US9422240B2
  申请人：——

  公开号：US9422240B2

  公开（公告）日：2016-08-23
• [EN] OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS D'OXAZOLINE POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL (CNS)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011057973A1

  公开（公告）日：2011-05-19

  The invention relates to compounds of formula (I) wherein the definitions of X, R and R1 are provided in claim 1. It has now been found that the compounds of formula (I) have a good affinity to the trace amine associated receptors (TAARs), especially for TAARl. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.